Characterization of a proton-activated, outwardly rectifying anion channel.
Anion channels are present in every mammalian cell and serve many different functions, including cell volume regulation, ion transport across epithelia, regulation of membrane potential and vesicular acidification. Here we characterize a proton-activated, outwardly rectifying current endogenously expressed in HEK293 cells. Binding of three to four protons activated the anion permeable channels at external pH below 5.5 (50% activation at pH 5.1). The proton-activated current is strongly outwardly rectifying, due to an outwardly rectifying single channel conductance and an additional voltage dependent facilitation at depolarized membrane potentials. The anion channel blocker 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS) rapidly and potently inhibited the channel (IC50: 2.9 microm). Flufenamic acid blocked this channel only slowly, while mibefradil and amiloride at high concentrations had no effect. As determined from reversal potential measurements under bi-ionic conditions, the relative permeability sequence of this channel was SCN-> I-> NO3-> Br-> Cl-. None of the previously characterized anion channel matches the properties of the proton-activated, outwardly rectifying channel. Specifically, the proton-activated and the volume-regulated anion channels are two distinct and separable populations of ion channels, each having its own set of biophysical and pharmacological properties. We also demonstrate endogenous proton-activated currents in primary cultured hippocampal astrocytes. The proton-activated current in astrocytes is also carried by anions, strongly outwardly rectifying, voltage dependent and inhibited by DIDS. Proton-activated, outwardly rectifying anion channels therefore may be a broadly expressed part of the anionic channel repertoire of mammalian cells.
Lambert
Sachar
S
Experimentelle und klinische Pharmakologie und Toxikologie, Gebäude 46, Uniklinikum des Saarlandes, 66421 Homburg, Germany.
Oberwinkler
Johannes
J
D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid / Q000494:pharmacology; D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D000838:Anions / Q000378:metabolism*; D001253:Astrocytes / Q000166:cytology; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002460:Cell Line; D002712:Chlorides / Q000378:metabolism; D004232:Diuretics / Q000494:pharmacology; D006624:Hippocampus / Q000166:cytology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007038:Hypotonic Solutions; D007473:Ion Channels / Q000502:physiology*; D007668:Kidney / Q000166:cytology; D008274:Magnesium / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D020748:Mibefradil / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D011522:Protons
D000838:Anions; D002121:Calcium Channel Blockers; D002712:Chlorides; D004232:Diuretics; D007038:Hypotonic Solutions; D007473:Ion Channels; D011522:Protons; D020748:Mibefradil; D000584:Amiloride; D008274:Magnesium; D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; D002118:Calcium